Akoya Biosciences, Inc. AKYA
We take great care to ensure that the data presented and summarized in this overview for Akoya Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AKYA
View all-
Blue Water Life Science Advisors, LP Larkspur, CA4.7MShares$10.1 Million11.23% of portfolio
-
Black Rock Inc. New York, NY1.5MShares$3.24 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.48MShares$3.21 Million0.0% of portfolio
-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX790KShares$1.71 Million3.97% of portfolio
-
Geode Capital Management, LLC Boston, MA562KShares$1.21 Million0.0% of portfolio
-
State Street Corp Boston, MA453KShares$979,1190.0% of portfolio
-
Parkman Healthcare Partners LLC Stamford, CT376KShares$812,4420.14% of portfolio
-
Gsa Capital Partners LLP London, X0311KShares$671,0450.06% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY271KShares$586,2240.01% of portfolio
-
Peddock Capital Advisors, LLC235KShares$506,9950.15% of portfolio
Latest Institutional Activity in AKYA
Top Purchases
Top Sells
About AKYA
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Insider Transactions at AKYA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 29
2024
|
Pascal Bamford Chief Clinical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+24.58%
|
-
|
|
Jun 11
2024
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
7,500
-3.23%
|
$15,000
$2.08 P/Share
|
|
Jun 11
2024
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+3.13%
|
$0
$0.3 P/Share
|
|
Jun 06
2024
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
7,500
-3.23%
|
$15,000
$2.01 P/Share
|
|
Jun 06
2024
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+3.13%
|
$0
$0.3 P/Share
|
|
Apr 01
2024
|
John Frederick Ek CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,272
-7.32%
|
$57,088
$4.56 P/Share
|
|
Mar 23
2024
|
Niro Ph.D Ramachandran Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,006
-0.96%
|
$8,024
$4.79 P/Share
|
|
Mar 23
2024
|
Frederic Pla Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,006
-1.94%
|
$8,024
$4.79 P/Share
|
|
Mar 23
2024
|
Brian Mc Kelligon President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,135
-3.08%
|
$28,540
$4.79 P/Share
|
|
Mar 20
2024
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
7,500
-3.13%
|
$30,000
$4.97 P/Share
|
|
Mar 20
2024
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+3.04%
|
$0
$0.3 P/Share
|
|
Mar 13
2024
|
Robert G Shepler Director |
BUY
Bona fide gift
|
Indirect |
369,592
+50.0%
|
-
|
|
Mar 13
2024
|
Robert G Shepler Director |
SELL
Bona fide gift
|
Indirect |
369,592
-100.0%
|
-
|
|
Mar 13
2024
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
7,500
-3.23%
|
$30,000
$4.94 P/Share
|
|
Mar 01
2024
|
Niro Ph.D Ramachandran Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,305
-1.09%
|
$13,830
$6.03 P/Share
|
|
Mar 01
2024
|
Frederic Pla Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,049
-1.94%
|
$12,294
$6.03 P/Share
|
|
Mar 01
2024
|
Jennifer Kamocsay General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,283
-3.2%
|
$19,698
$6.03 P/Share
|
|
Mar 01
2024
|
Brian Mc Kelligon President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,244
-2.68%
|
$61,464
$6.03 P/Share
|
|
Feb 22
2024
|
John Frederick Ek CFO |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+15.22%
|
-
|
|
Feb 22
2024
|
Niro Ph.D Ramachandran Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+14.16%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 268K shares |
|---|---|
| Exercise of conversion of derivative security | 45K shares |
| Bona fide gift | 370K shares |
| Payment of exercise price or tax liability | 43.3K shares |
|---|---|
| Open market or private sale | 52.5K shares |
| Bona fide gift | 370K shares |